Literature DB >> 16044413

In vitro release of clomipramine HCl and buprenorphine HCl from poly adipic anhydride (PAA) and poly trimethylene carbonate (PTMC) blends.

Rassoul Dinarvand1, Mohammed Massoud Alimorad, Massoud Amanlou, Hamid Akbari.   

Abstract

Controlled drug-delivery technology is concerned with the systematic release of a pharmaceutical agent to maintain a therapeutic level of the drug in the body for modulated and/or prolonged periods of time. This may be achieved by incorporating the therapeutic agent into a degradable polymer vehicle, which releases the agent continuously as the matrix erodes. In this study, poly trimethylene carbonate (PTMC), an aliphatic polycarbonate, and poly adipic anhydride (PAA), an aliphatic polyanhydride, were synthesized via melt condensation and ring-opening polymerization of trimethylene carbonate and adipic acid, respectively. The release of clomipramine HCl and buprenorphine HCl from discs prepared with the use of PTMC-PAA blends in phosphate buffer (pH 7.4) are also described. Clomipramine HCl and buprenorphine HCl were both used as hydrophilic drug models. Theoretical treatment of the data with the Peppas model revealed that release of clomipramine HCl (5%) in devices containing 70% PTMC or more followed a Fickian diffusion model. However, the releases of buprenorphine HCl (5%) in the same devices were anomalous. For devices containing 50% and more PAA, surface erosion may play a significant role in the release of both molecules. (c) 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044413     DOI: 10.1002/jbm.a.30398

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  4 in total

Review 1.  Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

Authors:  Heidi M Mansour; Minji Sohn; Abeer Al-Ghananeem; Patrick P Deluca
Journal:  Int J Mol Sci       Date:  2010-09-15       Impact factor: 5.923

2.  Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.

Authors:  L DeTolla; R Sanchez; E Khan; B Tyler; M Guarnieri
Journal:  J Vet Med       Date:  2014-11-27

3.  Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

Authors:  Michael Guarnieri; Betty M Tyler; Louis Detolla; Ming Zhao; Barry Kobrin
Journal:  J Pharm Bioallied Sci       Date:  2014-01

4.  Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.

Authors:  Ameya R Kirtane; Omar Abouzid; Daniel Minahan; Taylor Bensel; Alison L Hill; Christian Selinger; Anna Bershteyn; Morgan Craig; Shirley S Mo; Hormoz Mazdiyasni; Cody Cleveland; Jaimie Rogner; Young-Ah Lucy Lee; Lucas Booth; Farhad Javid; Sarah J Wu; Tyler Grant; Andrew M Bellinger; Boris Nikolic; Alison Hayward; Lowell Wood; Philip A Eckhoff; Martin A Nowak; Robert Langer; Giovanni Traverso
Journal:  Nat Commun       Date:  2018-01-09       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.